574 related articles for article (PubMed ID: 27357054)
1. Dogfish glucagon analogues counter hyperglycaemia and enhance both insulin secretion and action in diet-induced obese diabetic mice.
O'Harte FP; Ng MT; Lynch AM; Conlon JM; Flatt PR
Diabetes Obes Metab; 2016 Oct; 18(10):1013-24. PubMed ID: 27357054
[TBL] [Abstract][Full Text] [Related]
2. Novel dual agonist peptide analogues derived from dogfish glucagon show promising in vitro insulin releasing actions and antihyperglycaemic activity in mice.
O'Harte FP; Ng MT; Lynch AM; Conlon JM; Flatt PR
Mol Cell Endocrinol; 2016 Aug; 431():133-44. PubMed ID: 27179756
[TBL] [Abstract][Full Text] [Related]
3. Beneficial long-term antidiabetic actions of N- and C-terminally modified analogues of apelin-13 in diet-induced obese diabetic mice.
Parthsarathy V; Hogg C; Flatt PR; O'Harte FPM
Diabetes Obes Metab; 2018 Feb; 20(2):319-327. PubMed ID: 28730728
[TBL] [Abstract][Full Text] [Related]
4. Glucagon receptor antagonist and GIP agonist combination for diet-induced obese mice.
McShane LM; Irwin N; O'Flynn D; Franklin ZJ; Hewage CM; O'Harte FP
J Endocrinol; 2016 Jun; 229(3):319-30. PubMed ID: 27098830
[TBL] [Abstract][Full Text] [Related]
5. Two novel glucagon receptor antagonists prove effective therapeutic agents in high-fat-fed and obese diabetic mice.
O'Harte FP; Franklin ZJ; Irwin N
Diabetes Obes Metab; 2014 Dec; 16(12):1214-22. PubMed ID: 25060150
[TBL] [Abstract][Full Text] [Related]
6. A novel GLP-1/xenin hybrid peptide improves glucose homeostasis, circulating lipids and restores GIP sensitivity in high fat fed mice.
Hasib A; Ng MT; Khan D; Gault VA; Flatt PR; Irwin N
Peptides; 2018 Feb; 100():202-211. PubMed ID: 29412820
[TBL] [Abstract][Full Text] [Related]
7. desHis¹Glu⁹-glucagon-[mPEG] and desHis¹Glu⁹(Lys³⁰PAL)-glucagon: long-acting peptide-based PEGylated and acylated glucagon receptor antagonists with potential antidiabetic activity.
Irwin N; Franklin ZJ; O'Harte FP
Eur J Pharmacol; 2013 Jun; 709(1-3):43-51. PubMed ID: 23562625
[TBL] [Abstract][Full Text] [Related]
8. Anti-diabetic actions of esculentin-2CHa(1-30) and its stable analogues in a diet-induced model of obesity-diabetes.
Vasu S; Ojo OO; Moffett RC; Conlon JM; Flatt PR; Abdel-Wahab YHA
Amino Acids; 2017 Oct; 49(10):1705-1717. PubMed ID: 28836148
[TBL] [Abstract][Full Text] [Related]
9. Comparison of independent and combined metabolic effects of chronic treatment with (pGlu-Gln)-CCK-8 and long-acting GLP-1 and GIP mimetics in high fat-fed mice.
Irwin N; Hunter K; Montgomery IA; Flatt PR
Diabetes Obes Metab; 2013 Jul; 15(7):650-9. PubMed ID: 23388064
[TBL] [Abstract][Full Text] [Related]
10. [I10W]tigerinin-1R enhances both insulin sensitivity and pancreatic beta cell function and decreases adiposity and plasma triglycerides in high-fat mice.
Srinivasan DK; Ojo OO; Owolabi BO; Conlon JM; Flatt PR; Abdel-Wahab YH
Acta Diabetol; 2016 Apr; 53(2):303-15. PubMed ID: 26138324
[TBL] [Abstract][Full Text] [Related]
11. Esculentin-2CHa-Related Peptides Modulate Islet Cell Function and Improve Glucose Tolerance in Mice with Diet-Induced Obesity and Insulin Resistance.
Ojo OO; Srinivasan DK; Owolabi BO; Vasu S; Conlon JM; Flatt PR; Abdel-Wahab YH
PLoS One; 2015; 10(10):e0141549. PubMed ID: 26512980
[TBL] [Abstract][Full Text] [Related]
12. The effects of exendin-4 treatment on graft failure: an animal study using a novel re-vascularized minimal human islet transplant model.
Sahraoui A; Winzell MS; Gorman T; Smith DM; Skrtic S; Hoeyem M; Abadpour S; Johansson L; Korsgren O; Foss A; Scholz H
PLoS One; 2015; 10(3):e0121204. PubMed ID: 25793295
[TBL] [Abstract][Full Text] [Related]
13. Benefits of Sustained Upregulated Unimolecular GLP-1 and CCK Receptor Signalling in Obesity-Diabetes.
Tanday N; English A; Lafferty RA; Flatt PR; Irwin N
Front Endocrinol (Lausanne); 2021; 12():674704. PubMed ID: 34054734
[TBL] [Abstract][Full Text] [Related]
14. Glucagon from the phylogenetically ancient paddlefish provides a template for the design of a long-acting peptide with effective anti-diabetic and anti-obesity activities.
Graham GV; Conlon JM; Abdel-Wahab YH; Flatt PR
Eur J Pharmacol; 2020 Jul; 878():173101. PubMed ID: 32320703
[TBL] [Abstract][Full Text] [Related]
15. The frog skin host-defense peptide CPF-SE1 improves glucose tolerance, insulin sensitivity and islet function and decreases plasma lipids in high-fat fed mice.
Srinivasan D; Ojo OO; Owolabi BO; Conlon JM; Flatt PR; Abdel-Wahab YHA
Eur J Pharmacol; 2015 Oct; 764():38-47. PubMed ID: 26123844
[TBL] [Abstract][Full Text] [Related]
16. A Novel CCK-8/GLP-1 Hybrid Peptide Exhibiting Prominent Insulinotropic, Glucose-Lowering, and Satiety Actions With Significant Therapeutic Potential in High-Fat-Fed Mice.
Irwin N; Pathak V; Flatt PR
Diabetes; 2015 Aug; 64(8):2996-3009. PubMed ID: 25883113
[TBL] [Abstract][Full Text] [Related]
17. A novel neurotensin/xenin fusion peptide enhances β-cell function and exhibits antidiabetic efficacy in high-fat fed mice.
Perry RA; Craig SL; Gault VA; Flatt PR; Irwin N
Biosci Rep; 2021 Aug; 41(8):. PubMed ID: 34370015
[TBL] [Abstract][Full Text] [Related]
18. Taurine supplementation prevents morpho-physiological alterations in high-fat diet mice pancreatic β-cells.
Ribeiro RA; Santos-Silva JC; Vettorazzi JF; Cotrim BB; Mobiolli DD; Boschero AC; Carneiro EM
Amino Acids; 2012 Oct; 43(4):1791-801. PubMed ID: 22418865
[TBL] [Abstract][Full Text] [Related]
19. Sustained treatment with a stable long-acting oxyntomodulin analogue improves metabolic control and islet morphology in an experimental model of type 1 diabetes.
Irwin N; Pathak V; Pathak NM; Gault VA; Flatt PR
Diabetes Obes Metab; 2015 Sep; 17(9):887-95. PubMed ID: 26095087
[TBL] [Abstract][Full Text] [Related]
20. A novel glucagon-like peptide-1 (GLP-1)/glucagon hybrid peptide with triple-acting agonist activity at glucose-dependent insulinotropic polypeptide, GLP-1, and glucagon receptors and therapeutic potential in high fat-fed mice.
Gault VA; Bhat VK; Irwin N; Flatt PR
J Biol Chem; 2013 Dec; 288(49):35581-91. PubMed ID: 24165127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
